[{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Luminous Ventures"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Montanide ISA 51VG","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI-SCoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Treos Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer.

                          Product Name : PolyPEPI-1018

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 31, 2021

                          Lead Product(s) : PolyPEPI-1018

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Luminous Ventures

                          Deal Size : $14.0 million

                          Deal Type : Financing

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : PolyPEPI-SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant was safe in two mouse models and elicited highly specific, TH1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 19, 2020

                          Lead Product(s) : PolyPEPI-SCoV-2 Peptide Vaccine,Montanide ISA 51VG

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 15, 2020

                          Lead Product(s) : PolyPEPI-SCoV-2

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Treos plans to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 29, 2020

                          Lead Product(s) : PolyPEPI1018

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank